Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xanthus Will Develop Oral Fludarabine For U.S. Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering AG opts to out-license the oncologic rather than invest in further clinical study to support U.S. approval of the new dosage form.

You may also be interested in...



NICE Recommends Against Fludarabine For First-Line Treatment Of CLL

Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.

NICE Recommends Against Fludarabine For First-Line Treatment Of CLL

Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.

Xanthus To Develop Lung Cancer Therapy Following Deal With Schering AG

Xanthus licenses the peptide PD045, which management originally developed at Diatide prior to acquisition by Schering AG.

Topics

UsernamePublicRestriction

Register

PS063294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel